Infocom And KNIME GmbH Jointly Develop Modules for Drug Development Technology
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Infocom Corp, a system developer for pharmaceutical research facilities, has signed a licensing agreement with the German firm KNIME GmbH for developing and marketing business computer processing modules based on KNIME, a work flow platform designed to assist drug development research. KNIME, developed by Konstanz University in Germany, is an open system platform which is customizable for different modules and systems. Additionally, Infocom's licensing agreements with Hungarian company ChemAxon and KNIME have allowed it to develop the cheminformatics program suite JChem Node Extension, expected to launch in February 2008. (Click here for more-Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.